FDA Wants Preemptive Lupus Treatment Suit Nixed
The U.S. Food and Drug Administration on Monday pushed back against Health Science Funding LLC's novel bid for a declaration that labeling on its lupus treatment Prastera complies with FDA requirements...To view the full article, register now.
Already a subscriber? Click here to view full article